Laurus Labs Reports Mixed Q1 Results, Net Sales Reach 5-Quarter High

Laurus Labs, a largecap pharmaceutical company, recently announced its financial results for the quarter ended March 2024. The company has seen a negative financial performance in this quarter, with a score of -12, which has improved from -26 in the last three months.

Despite this, there are some positive aspects to Laurus Labs' financials. The company's net sales for the quarter were the highest in the last five quarters, at Rs 1,439.67 crore. The near-term sales trend is also positive.

However, there are also some areas that are not performing well for Laurus Labs. The Profit Before Tax (PBT) less Other Income for the quarter was at Rs 88.74 crore, which is a decrease of 38.98% compared to the same period last year. The near-term trend for PBT is also very negative. Similarly, the Profit After Tax (PAT) for the quarter was at Rs 75.61 crore, a decrease of 26.6% compared to the previous year. The near-term trend for PAT is also very negative.

Another concerning aspect is the company's interest cost, which has grown by 24.20% over the previous half-year period. This signifies increased borrowings for the company. Additionally, the company's non-operating income for the quarter was at its highest in the last five quarters, at Rs 18.53 crore. However, this increase in income from non-business activities may not be sustainable.

Despite these challenges, MarketsMOJO has given a 'Hold' call for Laurus Labs' stock. Investors should keep an eye on the company's financial performance in the coming quarters to make informed decisions.